Welcome to Show the Receipts, a series where we ask interesting people to share exactly how much it costs to get shit done.

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Titled “State of the Industry—The Evolving Landscape of Healthcare Coverage and Access in 2025,” 1 the goal of the Access USA ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity medications compared to lifestyle modification alone. Results indicate that ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

Wegovy is a prescription medication designed for chronic weight management, offering hope to individuals struggling with ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

According to the Association’s 2025 Statistics Update: ...

Many people who have struggled with their weight have been told to “eat less and move more.” Others have spent years juggling ...

Fortunately, with President Trump’s leadership on the issue, he can turn the tide in the quest to end obesity. There’s a ...

Diabetes and obesity remain at the top of the state's health issues.